NASDAQ:VERU Veru (VERU) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free VERU Stock Alerts $1.65 +0.16 (+10.81%) (As of 03:09 PM ET) Add Compare Share Share Today's Range$1.44▼$1.7250-Day Range$0.55▼$1.7952-Week Range$0.36▼$1.92Volume3.44 million shsAverage Volume2.39 million shsMarket Capitalization$241.67 millionP/E RatioN/ADividend YieldN/APrice Target$3.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Veru alerts: Email Address Veru MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside120.0% Upside$3.33 Price TargetShort InterestBearish7.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.26) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector686th out of 924 stocksBiotechnology Industry10th out of 19 stocks 3.4 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVeru has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.55% of the outstanding shares of Veru have been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Veru has recently increased by 11.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERU. Previous Next 2.9 News and Social Media Coverage News SentimentVeru has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Veru this week, compared to 1 article on an average week.Search Interest27 people have searched for VERU on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows10 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have not sold or bought any company stock.Percentage Held by Insiders14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to decrease in the coming year, from ($0.26) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Veru Stock (NASDAQ:VERU)Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Read More VERU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERU Stock News HeadlinesMay 2, 2024 | globenewswire.comVeru to Present at the GLP-1 Based Therapeutics SummitMay 1, 2024 | globenewswire.comVeru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024May 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.May 1, 2024 | americanbankingnews.comVeru (NASDAQ:VERU) Share Price Passes Above Two Hundred Day Moving Average of $0.78April 30, 2024 | globenewswire.comVeru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossApril 30, 2024 | finance.yahoo.comPalisade Capital Management Welcomes Chris Mashia to Small Cap Core and Smid Cap Core Equity StrategiesApril 25, 2024 | globenewswire.comVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11April 19, 2024 | markets.businessinsider.comNetflix To Stop Sharing Subscriber Data; Stock DipsMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 1, 2024 | finance.yahoo.comVeru Announces Date of 2024 Annual Meeting of ShareholdersMarch 29, 2024 | morningstar.comVeru IncMarch 22, 2024 | globenewswire.comVeru Reschedules Annual Meeting of ShareholdersMarch 21, 2024 | bizjournals.comWynwood offices targeted in $102M foreclosureMarch 19, 2024 | msn.comNaksha Saran plays a bike taxi driver in her next filmMarch 16, 2024 | ca.finance.yahoo.comVERU Mar 2024 0.500 putMarch 12, 2024 | globenewswire.comVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight LossMarch 11, 2024 | finance.yahoo.comVERU Mar 2024 1.500 putMarch 9, 2024 | finance.yahoo.comVERU Jan 2025 17.000 callMarch 9, 2024 | finance.yahoo.comVERU Mar 2024 0.500 callMarch 9, 2024 | finance.yahoo.comVERU Mar 2024 3.000 putMarch 1, 2024 | finance.yahoo.comVERU Mar 2024 2.500 putFebruary 28, 2024 | msn.comVeru gets Nasdaq notice related to delayed quarterly report on form 10-QFebruary 27, 2024 | globenewswire.comVeru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-QFebruary 25, 2024 | benzinga.comVeru Stock (NASDAQ:VERU), Analyst Ratings, Price Targets, PredictionsFebruary 20, 2024 | finance.yahoo.comVeru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight LossFebruary 20, 2024 | globenewswire.comVeru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight LossFebruary 16, 2024 | finance.yahoo.comVERU Feb 2024 0.500 callSee More Headlines Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/02/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPersonal Products Current SymbolNASDAQ:VERU CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees189Year FoundedN/APrice Target and Rating Average Stock Price Target$3.33 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside+101.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,150,000.00 Net Margins-405.04% Pretax Margin-390.73% Return on Equity-257.92% Return on Assets-107.27% Debt Debt-to-Equity RatioN/A Current Ratio3.21 Quick Ratio2.79 Sales & Book Value Annual Sales$16.30 million Price / Sales14.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book7.54Miscellaneous Outstanding Shares146,380,000Free Float125,595,000Market Cap$242.65 million OptionableOptionable Beta-0.48 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Mitchell S. Steiner F.A.C.S. (Age 63)M.D., Chairman, President & CEO Comp: $885.32kDr. Harry Fisch F.A.C.S. (Age 65)M.D., Vice Chairman & Chief Corporate Officer Ms. Michele Greco (Age 65)CFO & Chief Administrative Officer Comp: $493.7kDr. K. Gary Barnette Ph.D. (Age 56)Chief Scientific Officer Comp: $676.27kMr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsMr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryMr. Kevin J. Gilbert CPAJ.D., Executive Vice President of Corporate DevelopmentMr. Martin Tayler (Age 55)Executive Vice President of FC2 Global Operations Comp: $180.51kMr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselDr. Domingo Rodriguez M.D. (Age 62)Executive Vice President of Global Clinical Operations More ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSNature's Sunshine ProductsNASDAQ:NATRG1 TherapeuticsNASDAQ:GTHXEliem TherapeuticsNASDAQ:ELYMDesign TherapeuticsNASDAQ:DSGNView All CompetitorsInstitutional OwnershipChoreo LLCBought 91,916 shares on 5/2/2024Ownership: 0.063%Rosalind Advisors Inc.Bought 500,000 shares on 4/25/2024Ownership: 3.074%180 Wealth Advisors LLCBought 170,750 shares on 4/16/2024Ownership: 0.117%Perceptive Advisors LLCBought 4,494,821 shares on 2/26/2024Ownership: 4.058%Octagon Capital Advisors LPBought 3,800,000 shares on 2/15/2024Ownership: 2.761%View All Institutional Transactions VERU Stock Analysis - Frequently Asked Questions Should I buy or sell Veru stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERU shares. View VERU analyst ratings or view top-rated stocks. What is Veru's stock price target for 2024? 4 Wall Street analysts have issued 1-year target prices for Veru's shares. Their VERU share price targets range from $2.00 to $5.00. On average, they anticipate the company's share price to reach $3.33 in the next twelve months. This suggests a possible upside of 120.0% from the stock's current price. View analysts price targets for VERU or view top-rated stocks among Wall Street analysts. How have VERU shares performed in 2024? Veru's stock was trading at $0.72 at the beginning of the year. Since then, VERU stock has increased by 110.4% and is now trading at $1.5150. View the best growth stocks for 2024 here. When is Veru's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VERU earnings forecast. How can I listen to Veru's earnings call? Veru will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "8861692". How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) posted its earnings results on Monday, April, 1st. The company reported ($0.09) EPS for the quarter. The firm earned $2.14 million during the quarter. Veru had a negative net margin of 405.04% and a negative trailing twelve-month return on equity of 257.92%. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). Who are Veru's major shareholders? Veru's stock is owned by a variety of retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (3.07%), 180 Wealth Advisors LLC (0.12%) and Choreo LLC (0.06%). Insiders that own company stock include Harry Fisch, Lucy Lu and Mario Eisenberger. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERU) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTrump just won 2024Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
